Publications found:
73,128
Sort by:
Endometriosis - Epidemiology Insights to 2025
US$ 2,950.00
... epidemiology historical and forecasted data of Endometriosis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease ... Endometriosis market. Identifying prevalent patient populations as well as risk factors in the global Endometriosis ...
July 2017
40 pages
Cytomegalovirus (CMV) Infection- Epidemiology Insights to 2025
US$ 2,950.00
... 10 years epidemiology historical and forecasted data of Cytomegalovirus (CMV) Infection prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with ...
July 2017
40 pages
Peanut Allergy - Epidemiology Insights to 2025
US$ 2,950.00
... risk factors, disease burden with special emphasis on the unmet medical needs associated with the Peanut Allergy. The report contains the targeted patient populations and the forecast ...
July 2017
40 pages
Severe Psoriasis - Epidemiology Insights to 2025
US$ 2,950.00
... risk factors, disease burden with special emphasis on the unmet medical needs associated with the Severe Psoriasis. The report contains the targeted patient populations and the forecast ...
July 2017
40 pages
Sickle Cell Disease - Epidemiology Insights to 2025
US$ 2,950.00
... the trends shaping and driving the global Sickle Cell Disease market. Identifying prevalent patient populations as well as risk factors in the global Sickle Cell Disease market will help to improve product design ...
July 2017
40 pages
Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, and Services), Technology (Deep Learning, Querying Method, Natural Language Processing, and Context Aware Processing), Application (Robot-assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Dosage Error Reduction, Clinical Trial Participant Identifier, Preliminary Diagnosis, and Others), and End User (Healthcare Provider, Pharmaceutical & Biotechnology Company, Patient, and Payer) - Global Opportunity Analysis and Industry Forecast, 2017-2023
US$ 5,540.00
Artificial intelligence assists the machines to perform any task without human interventions. It ... Arabia South Africa Rest of LAMEA The other players of the artificial intelligence in healthcare market include (companies not profiled in the report): Shimadzu Recursion Pharmaceuticals ...
July 2017
160 pages
The US Onychomycosis Market (2017 Edition)
US$ 750.00
... The report entitled “The US Onychomycosis Market (2017 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value ...
July 2017
49 pages
Sickle Cell Disease Forecast in 10 Major Markets 2017-2027
US$ 6,150.00
... -populations within the main disease are also included at a country level across the 10-year forecast snapshot. These common Sickle cell disease co-morbidities include: Vaso ... on the impact from specific co-morbid conditions on sickle cell disease prevalent population. Identify sub-populations within sickle cell disease which require treatment. Gain an understanding of the ...
July 2017
44 pages
Market Access Impact (EU5) [Asthma/COPD]
US$ 2,575.00
... ’t know they exist. Market Access Impact: Asthma/COPD (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. You ... ; Novartis) Exploring Important Market Access Issues Market Access Impact: Asthma/COPD (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
July 2017
-
Market Access Impact (EU5) [Haemophilia B]
US$ 5,145.00
... the ones that are costing you market share. Market Access Impact: Haemophilia B (EU5) shows you how 7 barriers affect your market share, revealing which competitors you ... gamma; Shire) Exploring on Market Access issues Market Access Impact: Haemophilia B (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are ...
July 2017
-
Market Access Impact (EU5) [Parkinson's Disease]
US$ 5,145.00
... affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (EU5). Based on a survey of 150 neurologists from the EU5 countries, the report covers 8 major ...
July 2017
-
Market Access Impact (US) [Asthma/COPD]
US$ 2,575.00
... treatments get a market share bump of almost 5% because doctors can’t prescribe competitors. Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing ... furoate; GSK) Exploring Market Access Barriers Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands do doctors ...
July 2017
-
Market Access Impact (US) [Haemophilia B]
US$ 5,145.00
... the ones that are costing you market share. Market Access Impact: Haemophilia B (US) shows you how 7 barriers affect your market share, revealing which competitors you ... gamma; Shire) Exploring on Market Access issues Market Access Impact: Haemophilia B (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are ...
July 2017
-
Market Access Impact (US) [Parkinson's Disease]
US$ 5,145.00
... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Parkinson’s Disease (US). Based ... ; US Worldmeds) Exploring Market Access Barriers Market Access Impact: Parkinson’s Disease (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
July 2017
-
Medical Affairs Reputations (EU5) [Cancer Pain]
US$ 6,175.00
... your team seize the opportunity? The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a disappointing performance in the ... team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (EU5). Comparing 7 major cancer pain treatments from Kyowa Kirin, Mundipharma/Napp, Takeda ...
July 2017
-
Medical Affairs Reputations (EU5) [Melanoma]
US$ 6,175.00
... team gets wrong The medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists gave it the ... more often or back off a bit. Insight into Medical Affairs Teams for These Melanoma Treatments Imlygic (talimogene laherparepvec; Amgen) Keytruda (pembrolizumab; Merck ...
July 2017
-
Medical Affairs Reputations (US) [Cancer Pain]
US$ 6,175.00
Disappointing scores show that medical affairs teams need to up their game The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned ... team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (US). Comparing 6 major cancer pain treatments from Endo Pharmaceuticals, Insys Therapeutics, Mallinckrodt ...
July 2017
-
Medical Affairs Reputations (US) [Melanoma]
US$ 6,175.00
Find out what the leading medical affairs teams are doing right Medical affairs teams for two leading melanoma treatments are doing all the ... your team gets right, and where it’s going wrong in Medical Affairs Reputations: Melanoma (US). Comparing 8 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis ...
July 2017
-
Multiple Myeloma: KOL Insight [2017]
US$ 8,145.00
... (KOLs)? Which products and combinations are likely to succeed? Learn how KOLs see the MM market evolving in KOL Insight: Multiple Myeloma (MM). Twelve US and European KOLs provide candid insights ... Objectives Questions Asked See the Multiple Myeloma therapies covered Find out who the 6 US and 6 European KOLs are Sample Pages Top Takeaways ...
July 2017
-
NPS+ (EU5) [Growth Hormone Deficiency]
US$ 2,575.00
... how does each of the leading brands compare to its competitors? NPS+ Growth Hormone Deficiency (EU5) gives a unique insight into the overall brand health of 7 leading ... Brand Loyalty Issues NPS+ Growth Hormone Deficiency (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing growth hormones. You’ll discover How ...
July 2017
-
NPS+ (US) [Growth Hormone Deficiency]
US$ 2,575.00
... how does each of the leading brands compare to its competitors? NPS+ Growth Hormone Deficiency (US) gives a unique insight into the overall brand health of 7 leading ... and 7th June 2017. Explore Important Brand Loyalty Issues NPS+ Growth Hormone Deficiency (US) explores key issues affecting brand loyalty for drug manufacturers ...
July 2017
-
RCC: KOL Insight [2017]
US$ 8,145.00
How will new combination regimens impact the RCC treatment landscape? The treatment of advanced RCC has been transformed in recent years as VEGF ... for oncologists? In this report six US and six EU KOLs offer their candid insights on ten marketed therapies and five pipeline drugs. Take ... and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success. FirstWord ...
July 2017
-
Rheumatoid Arthritis [2017]: Bulletin #1
US$ 1,045.00
... treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a complete response letter, in April 2017, regarding Elli ... product’s delayed entry to this market; the FDA’s approval, in May 2017, of Sanofi and Regeneron’s second-in-class, anti-interleukin-6 (IL-6) inhibitor, Kevzara ...
July 2017
-
SLE: KOL Insight [2017]
US$ 8,145.00
... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Systemic Lupus Erythematosus (SLE). Twelve North American and European KOLs give their insight on one marketed product, one ...
July 2017
-
Type 2 Diabetes Mellitus [2016]: Bulletin #3
US$ 1,045.00
... presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line ... show superiority for cardiovascular end-point; will it have a role in type 2 diabetes treatment algorithm? If so where? How do KOLs see Bydureon in relation to Trulicity ...
July 2017
-
Ulcerative Colitis [2016]: Bulletin #3
US$ 1,045.00
... events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation ...
July 2017
-
What do Patients want from Pharma? The Real Patient-Centric Perspective
US$ 695.00
What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want? Is patient centricity coming of age? The patient voice is becoming increasingly influential ... from patients and embed a patient centric approach across their organisation. For a real patient-centric perspective turn to What do Patients want from Pharma 2017? In this revealing report, 12 US and EU patient ...
July 2017
-
Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)
US$ 800.00
... goal is to minimize the frequency and severity of angioedema episodes. The global hereditary angioedema market is set to experience favourable growth driven by factors ... and oral medication for HAE attacks. The report “Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)” analyses the ...
June 2017
66 pages
Global Microbiome Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2016 - 2023
US$ 3,950.00
The report on global microbiome therapeutics market evaluates the growth trends of the industry through historical study ... competitive landscape of the worldwide market with company profiles of key players such as Enterome Bioscience, MaaT Pharma, MicroBiome Therapeutics LLC, OpenBiome, Rebiotix, Inc ...
June 2017
107 pages
COPD [2017]: Bulletin #1
US$ 1,045.00
... key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate ...
June 2017
-
Market Access Impact (EU5) [MS]
US$ 5,145.00
... them at the same rates as other treatments. Market Access Impact: Multiple Sclerosis (EU5) shows you how widely prescribed your brand ... ) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access Barriers Market Access Impact: Multiple Sclerosis (EU5) explores key issues affecting drug manufacturers. You ...
June 2017
-
Market Access Impact (US) [MS]
US$ 5,145.00
... instead of its competitors. Market Access Impact: Multiple Sclerosis (US) shows you how 7 barriers affect your market share, revealing how ... ; Biogen) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access Barriers Market Access Impact: Multiple Sclerosis (US) explores key issues affecting drug ...
June 2017
-
MSL stakeholder engagement: meeting expectations
US$ 695.00
MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover on this page 1. The executive ...
June 2017
-
NPS+ (EU5) [NSCLC]
US$ 2,575.00
... how does each of the leading brands compare to its competitors? NPS+ NSCLC (EU5) gives a unique insight into the overall brand health of 10 leading ... and 13th July 2017. Explore Important Brand Loyalty Issues NPS+ NSCLC (EU5) offers valuable insight into brand loyalty from the perspective ...
June 2017
-
NPS+ (US) [NSCLC]
US$ 2,575.00
... each of the leading brands compare to its competitors? NPS+ NSCLC (US) gives a unique insight into the overall brand ... 2017. Explore Important Brand Loyalty Issues NPS+ NSCLC (US) offers valuable insight into brand ... molecule and biologic treatments to patients with NSCLC. You’ll discover: How satisfied doctors ...
June 2017
-
Psoriasis [2017]
US$ 8,145.00
... which class of product? Will payers influence the uptake of pipeline psoriasis drugs? If so, will this be based purely on cost and ... a division with a specific focus on the treatment of inflammatory conditions, including psoriasis, at leading teaching hospitals in Germany. Money Back Guarantee At FirstWord, we ...
June 2017
-
Targeted Therapies in Asthma [2017]: Bulletin #2
US$ 1,045.00
... can be learned? Could differences in access to therapy in each European country that took part in the ... for Asthma) guidelines need to be modified? Is more head to head data needed for biologic therapies that ... be used in the treatment of severe eosinophilic asthma, and what challenges face AstraZeneca in terms ...
June 2017
-
Erectile Dysfunction (Ed) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Erectile Dysfunction (ED)' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of the ...
June 2017
196 pages
Esophageal Cancer - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Esophageal Cancer' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
June 2017
208 pages
Vasculitis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Esophageal Cancer' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement scenario; Public, Private, Medicare, ...
June 2017
163 pages
Varicose Veins - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Varicose Veins' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
June 2017
215 pages
Febrile Neutropenia - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Febrile Neutropenia' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
June 2017
148 pages
Fallopian Tube Cancer - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Fallopian Tube Cancer' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of the ...
June 2017
145 pages
Gastritis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Gastritis' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report ... , competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement scenario; Public, Private, Medicare, ...
June 2017
184 pages
